Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, The Oncology Institute, Inc. reported revenue of $503M, up 27.8% year over year. Operating margin was -7.2% and net margin -12.1%, on a free-cash-flow margin of -5.5% with capital expenditure at 0.6% of revenue. Every figure is computed directly from TOI's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $503M | -7.2% | -12.1% |
| FY2024 | $393M | -15.3% | -16.4% |
| FY2023 | $324M | -23.8% | -25.6% |
| FY2022 | $252M | -32.5% | 0.1% |
| FY2021 | $203M | -22.6% | -5.4% |
How does TOI compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AACG · ABSI · ACCS · ACHC · ACM · ADUS
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.